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126 Poster Session-IIAcute GVHD following sibling RIC transplants was analyzed in
110 patients (63 males; 47 females) with a median age of 46.5 years
(17263) transplanted between 1998 and 2008 for various malignant
and non-malignant indications. Fludarabine [120–150 mg/m2] with
either Cyclophosphamide [120 mg/kg] (n 5 87), Melphalan [140
mg/m2] (n 5 15), oral Busulfan [10 mg/kg] (n 5 6) or Cytosine ara-
binoside (n 5 2) was used for conditioning with peripheral blood
stem cells (PBSC) as graft source. GVHD prophylaxis included Cy-
closporine either alone [n5 19] or with low dose methotrexate [n5
53] or mycophenolate [n 5 38]. Nine patients received Antithymo-
cyte globulin (ATG) in addition. A median of 5.7  106 CD34/kg
(0.96218.9) cells was infused with a median neutrophil and platelet
recovery of 14 (5 – 33) and 17 days (0 – 157) respectively. Acute
GVHD occurred in 66 (60%) at a median of 29 days (12 – 86)
with grade II-IV GVHD in 46.3% and grade III– IV in 20.9%. Seven
patients (10.6%) died due to either acute GVHD or infection.
Chronic GVHD occurred in 56% of evaluable patients. At a median
of 28 months (range: 2 – 105), overall survival (OS) is 47.2% with an
OS of 43.9% with GVHD and 52.2% without GVHD (p5 0.434). A
number of variables were analysed including recipient and donor age
and gender, ABO incompatibility, conditioning regimen, GVHD
prophylaxis, use of ATG, cell dose, time to neutrophil recovery
and Absolute lymphocyte count (ALC) on day 15 and day 30 post
transplant. On univariate analysis, donor age (p5 0.015), neutrophil
recovery\ 15 days (p 5 0.013), Day 15 ALC . 0.6  109/L (p 5
0.038) and sex mismatched transplant (p 5 0.018) were identified
as risk factors for GVHD while diagnosis of AML (p 5 0.001), use
of Flu/Bu (p 5 0.033) and presence of major ABO incompatibility
(p 5 0.039) were risk factors identified as protective. On a multiple
logistic regression analysis (Table 1), donor age and sex mismatched
transplant continued to remain significant while Flu/Bu condition-
ing, diagnosis of AML and major ABO incompatibility remained
protective. A better understanding of the risk factors causing
GVHD will help in establishing better regimens for conditioning
and GVHD prophylaxis leading to improved survival with RIC
regimens.
Multivariate proportional hazard regression analysis of all pa-
tients
Variable Relative risk Confidence interval p valueDonor age 1.051 1.010 – 1.094 0.015
Sex mismatch 3.874 1.260 – 11.915 0.018
Diagnosis of AML 0.202 0.077 – 0.531 0.001
Flu/Bu conditioning 0.071 0.006 – 0.805 0.033
ABO major mismatch 0.206 0.070 – 0.934 0.039351
INTENSIVE EXTRA CORPOREAL PHOTOTHERAPY (ECP) COURSES IN
ACUTE GRAFT VERSUS HOST DISEASE (AGVHD) PATIENTS
Tassi, C., Giudice, V., Baldazzi, P., Guizzardi, A.M., Rago, E., Vitali, P.,
Zimotti, A., Pagliaro, P. Unita` Operativa di Immunoematologia e Tras-
fusionale, Bologna, Italy
AGVHD may occur in a high proportion of allo-transplanted pa-
tients and is one the main causes of death. ECP treatment may suc-
cessfully be employed in patients refractory or not eligible to high
doses steroid therapy. The ECP intensification, as well as the timely
start of the courses, are probably fundamental to enhance the prob-
ability and the rate of clinical response. Ten aGVHD III-IV patients,
7 males and 3 females, were enrolled. Four were adults and six were
children with liver, gut or skin localization. The mean time from
aGVHD diagnosis to ECP starting was seven days. Three ECP
were performed weekly for three consecutive weeks then two proce-
dures every two weeks were carried out in six months. A mean of 16
(6–29) procedures per patient was carried out, being 4 (1–6) months
the mean duration per treatment. Phenotype studies disclosed Treg
cells and circulating oligoclonal TCRVB subsets in in two and five
patients, respectively. Cyclosporine A was used as primary immuno-
suppressive drug in six patients or associated to MMF or tacrolimus
in two and one patients. One patient received MMF alone and four,
Infliximab (3–6 doses). Two patients died for progressive GVHDand in one ECP was stopped for severe CMV reactivation. Seven pa-
tients (78%) had fast and significant clinical recovery after the first
six, intensified ECP and the mean follow-up observed is of 29 (6–
50) months. One child responsive after seven ECP courses died for
acute liver failure, one month after the ECP had been concluded
One child relapsed and died for NB in the first year post transplan-
tation, two adults are alive with relapsed HL, the others are alive
without clinical or molecular signs of relapse. As regards phenotype
studies, in two responsive patients, not treated with Cyclosporine A,
Treg absolute counts tripled during ECP treatment while oligoclo-
nal TCRVB families disappeared in all responsive patients. Despite
the limited number of the subjects treated, the rapid clinical recovery
observed in these highly compromised patients enforces the indica-
tion to employ intensive ECP courses to accelerate the clinical re-
mission and to reduce the immunosuppression. As regards the
possible use of the Treg or the TCRVB oligoclonal subsets modifi-
cations as prognostic factors during ECP treatment, the true involve-
ment of these subpopulations is up to date, unclear. In particular
Cyclosporine A might inhibit the production of Tregs and probably,
other biological markers must be individuated.352
FASL, PERFORIN, AND TRAIL ARE NOT REQUIRED BY T CELL S FOR EP-
ITHELIAL DAMAGE IN A CUTANEOUS GVHD-LIKE REACTION ACROSS MI-
NOR HISTOCOMPATIBILITY ANTIGENS IN VITRO
Arditti, F.D., Goldgirsh, K., Friedman, T., Korngold, R. Hackensack Uni-
versity Medical Center, Hackensack, NJ
The role of Fas Ligand (FasL), Perforin, and TRAIL during the
immunopathological development of graft-versus-host disease
(GVHD) remains unclear. We utilized a recently established culture
system to pinpoint their role in mediating a cutaneous GVHD-like
reaction across minor histocompatibility antigens (miHA) by either
CD41 or CD81 T cell subsets. Despite the upregulation (27 6
3.2 to 43 6 5.1 MFI) of Fas on primary skin epithelial cells (pEC)
cocultured with T cells, FasL deficient B6Smn.C3H-Faslgld (Gld)
T cells killed C.B10-H2b (BALB.B) pEC as efficiently as normal
C57Bl/6 (B6) T cells (p . 0.5), suggesting that a FasL-independent
mechanism is active. Interferon gamma (IFN-g) was secreted by
both CD41 and CD81 separated normal T cell subsets, and they
were able to upregulate the expression of H2Kb. However, unsepa-
rated T cells induced more potent effects than either individual
CD41 (p\0.03) or CD81 (p\0.04) subset. The presence of IFN-
g had no effect on Fas expression, also consistent with the lack of
any such observable effect with the addition of recombinant IFN-g
to the cultures. By day 5 of incubation of pEC with Perforin-defi-
cient CD41 T cells, no dead cells were detected in the epithelial
layer, as compared with the onset of cytotoxicity already elicited by
normal, GLD, or TRAIL-deficient CD41 T cells. However, this
decreased reactivity of Perforin-deficient CD41 T cells was not
long lasting and was subsequently replaced by a less potent but still
efficient cytotoxic effect, as compared with that induced by normal
(p\ 0.002), FasL (p\ 0.02) or TRAIL-deficient (p\0.04) CD41
T cells. TRAIL-deficient T cells secreted higher amounts of
IFN-g.; but the CD81 TRAIL-deficient subset exhibited lowered
cytotoxicity against pEC. As found with T cells deficient in FasL
and Perforin, TRAIL-deficiency did not prevent the cytotoxic effect.
In summary, our results suggest that Fas-FasL, TRAIL and Perforin
are indeed involved in T cell mediated GVHD-like effects against
pEC, although neither of them are essential to severely damage the
epithelial cells. Rather, a key role for other known, as well as un-
known, cytotoxic pathways are indicated and should be examined.353
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